AbbVie vs Regeneron Pharmaceuticals
AbbVie is the larger business, with $61.16bn of revenue in fiscal 2025 against $14.34bn for Regeneron Pharmaceuticals (4.3 times as much). AbbVie grew faster (8.6% against 1.0%). Regeneron Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 31.4% against 6.9%.
| Latest fiscal year | AbbVieABBV, 2025 | Regeneron PharmaceuticalsREGN, 2025 |
|---|---|---|
| Revenue | $61.16bn | $14.34bn |
| Revenue growth | 8.6% | 1.0% |
| Net income | $4.23bn | $4.50bn |
| Operating margin | 24.6% | 24.9% |
| Net margin | 6.9% | 31.4% |
| Return on equity | — | 14.9% |
| Free cash flow | $17.82bn | $4.08bn |
| Cash | $5.23bn | $3.12bn |
| Total debt | $67.50bn | $1.99bn |
| Debt to equity | — | 6.4% |
| Dividend per share | $6.65 | — |
| Dividend yield | 2.4% | 0.4% |
| Share buybacks | $980m | $3.44bn |
| Employees | 57,000 | 15,410 |
| Market value | $505.48bn | $102.62bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 87 (Strong) | 86 (Strong) |
| Insider trades, 12 months | 0 buys, 6 sales | 0 buys, 105 sales |